Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators
Enadenotucirev (EnAd) is a chimeric group B adenovirus isolated by bioselection from a library of adenovirus serotypes. It replicates selectively in and kills a diverse range of carcinoma cells, shows effective anticancer activity in preclinical systems, and is currently undergoing phase I/II clinic...
Main Authors: | Dyer, A, Di, Y, Calderon, H, Illingworth, S, Kueberuwa, G, Tedcastle, A, Jakeman, P, Chia, S, Brown, A, Silva, M, Barlow, D, Beadle, J, Hermiston, T, Ferguson, D, Champion, B, Fisher, K, Seymour, L |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2016
|
Similar Items
-
Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators
by: Arthur Dyer, et al.
Published: (2017-03-01) -
Preclinical safety studies of enadenotucirev, a chimeric group B human-specific oncolytic adenovirus
by: Illingworth, S, et al.
Published: (2017) -
Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus
by: Sam Illingworth, et al.
Published: (2017-06-01) -
Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth
by: Tedcastle, A, et al.
Published: (2016) -
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
by: Machiels, JP, et al.
Published: (2019)